Stay updated on PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page.

Latest updates to the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page footer now shows Revision: v3.3.2, replacing Revision: v3.2.0.SummaryDifference0.1%

- Check28 days agoChange DetectedDeleted the funding/operating-status notice banner at the top of the study record page; the remaining study content is unchanged.SummaryDifference0.4%

- Check42 days agoChange DetectedNo significant changes to core content were detected; the updates appear to be minor editorial or formatting changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check71 days agoChange DetectedMajor change: page now carries a government-operating-status notice and a new version tag (v3.2.0) replacing the old one (v3.1.0).SummaryDifference3%

- Check78 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.1%

- Check92 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed. No changes to core content, pricing, stock, or time-sensitive information.SummaryDifference0.2%

Stay in the know with updates to PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PRS-343 & Atezolizumab in HER2+ Solid Tumors Clinical Trial page.